What does epigenetics have to do with risk for Alzheimer disease? Are our epigenetics immutable? What are the therapeutic implications? Those questions answered in this podcast.
What medications are in the pipeline that may help slow or even prevent the development of Alzheimer disease?
An expert discusses the latest guidelines to reduce brain injury in adults who are comatose after cardiac resuscitation.
Key details about an option for the treatment of drug-resistant epilepsy in patients who are not surgical candidates.
Alzheimer disease is not an equal opportunity employer. Insights about early life stressors and economic disadvantage.
What do the new AAN guidelines on SUDEP offer? Here’s a quick overview of the key facts.
In this podcast, Ann Scher, PhD, lead author in a recently published study, gives a succinct overview of the details and briefly discusses what the findings may suggest.